Abstract
Coupling CEA (CEACAM5) on tumor cells and CD3 on T-cells by CEAxCD3 bispecific antibodies activates the latter to destroy CEA-positive cancer cells. Clinical activity is, however, limited, in part by insufficient T-cell activation, dose-limiting toxicities or immunogenicity. Combination with CEA-targeted CD28-costimulation shall increase activity and, when sequentially given, reduce the risk of cytokine release syndrome. We present here preclinical data for the combination of NILK-2301 ± NILK-3301.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
